Biogen pays $900M to settle wide-ranging physician kickback claims

Looking to clear the deck ahead of its long-awaited lecanemab data release, Biogen agreed to pay the US government and states a whopping $900 million to settle seven-year-old allegations that it submitted false claims to Medicare and Medicaid by paying kickbacks to physicians to induce them to prescribe Biogen drugs.